Bora Pharmaceuticals' recent strategic maneuvers have significantly bolstered its presence in the Contract Development and Manufacturing Organization (CDMO) sector, showcasing its intent to become a top contender in the biomanufacturing industry. In a notable move, Bora has acquired a 30.5%
Bora Pharmaceuticals continues its robust expansion by acquiring a significant operational stake in Tanvex BioPharma, a deal set to close in early 2025. This strategic acquisition positions Bora as the largest shareholder in Tanvex, granting the company access to a commercial-scale production
The acquisition of a 30.5% stake in Tanvex Biopharma by Bora Pharmaceuticals is a pivotal development in the biotech sector. As the largest single corporate shareholder in Tanvex, Bora aims to leverage this strategic partnership to enhance its competitive edge in the global biopharmaceutical
The Korea Biopharma Excellence Awards (KBEA) 2024 marked a significant moment for Avantor, a leader in providing mission-critical products and services across life sciences and advanced technologies. Avantor’s recognition at these awards underscores their unwavering commitment to innovation and e
Regeneron Pharmaceuticals recently hit a roadblock in its quest to bring its experimental multiple myeloma drug, linvoseltamab, to market. Although the drug promises significant benefits to patients, manufacturing flaws at a third-party facility have delayed FDA approval. This analysis delves into
VGXI Inc., a prominent Contract Development and Manufacturing Organization (CDMO) specializing in nucleic acid biopharmaceuticals, is making significant strides in the biopharmaceutical industry. Their recent inclusion in the Biopharmaceutical Manufacturing Preparedness (BioMAP) Consortium
